UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The UK’s Medicines and Healthcare products Regulatory Agency said that following global reports of serious adverse events in ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

Following global reports of serious adverse events in older people, the government’s independent expert advisory body, the UK ...

A landmark global modeling study reveals that more than 2.8 billion people in 104 countries are at risk of chikungunya, with ...

The MHRA is working with the manufacturer of the IXCHIQ  vaccine, Valneva. This vaccine was approved by the MHRA in February 2025. There will be no impact on operational issues as this vaccine is not ...

This is a precautionary measure while the MHRA conducts the safety review. Following global reports of serious adverse events ...

The EMA's human medicines committee has recommended approval for Bavarian Nordic's chikungunya vaccine, which is shaping up to be the first alternative to a rival shot from Valneva. The CHIKV VLP ...

Europe is increasingly grappling with illness and deaths from extreme weather and the arrival of tropical diseases but it has ...